Asked by: Luke Murphy (Labour - Basingstoke)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to ensure NHS Trusts comply with NICE CG143 and national sickle cell clinical standards in the management of acute sickle cell crises, particularly in relation to timely escalation of analgesia and adherence to individual care plans.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The NHS England Sickle Cell and Thalassaemia Improvement Programme aims to address health inequalities through targeted interventions. A key priority for the programme has been supporting National Health Service trusts in the management of acute sickle cell crises.
The programme has rolled out seven sickle cell Emergency Department Bypass Accelerator Sites to provide rapid access to pain relief for uncomplicated vaso-occlusion crises. The sites across the country are mainly in areas with a high prevalence of sickle cell, with four based in London and three in the North of England. The accelerator sites operate a 24/7 service, providing patients with direct access to specialist sickle cell care, either through self-referral, ambulance pathways, or transfer between wards. An evaluation of the effectiveness of the units is being carried out by the National Institute for Health and Care Research with early indications suggesting significant improvements in time to analgesia as per the National Institute for Health and Care Excellence CG143 guideline. A full report is expected in Quarter four of 2026.
In 2024, NHS England funded a programme of work to ensure that all patients with sickle cell in London and Greater Manchester have access to a personalised digital care plan, with an ambition to expand to other regions when the technology becomes available.
Asked by: Bell Ribeiro-Addy (Labour - Clapham and Brixton Hill)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to increase diagnosis of sickle cell amongst patients of Latin American descent.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Government is committed to improving the lives of those living with rare diseases such as sickle cell disease. Helping patients get a final diagnosis faster is one of the four priorities of the UK Rare Diseases Framework. We published the annual England action plan in February 2025, where we report on the steps we have taken to advance this priority.
In England, there are around 17,000 people living with sickle cell disease, an inherited blood disorder with around 250 new cases a year. It is the fastest growing genetic condition in the country. It is generally more common in people of Black African and Black Caribbean heritage (77% of patients) however, we recognise that the condition is not unique to this community and NHS England remain committed to delivering quality improvement to all patients living with sickle cell.
All pregnant women in England are offered a blood test to find out if they carry a gene for thalassaemia. Those at high risk of being a sickle cell carrier are offered a test for sickle cell. As part of the National Health Service Antenatal Sickle Cell and Thalassaemia (SCT) Screening Programme, the Family Origin Questionnaire (FOQ) is mandatory for all booking blood requests. By recording accurate family origin details, the FOQ enables midwives to identify women at higher risk. For example, women with Latin American ancestry extending back two generations are considered high risk and are offered screening accordingly.
Asked by: Shivani Raja (Conservative - Leicester East)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether the Sickle Cell Disease Quality Improvement Programme will continue when the Department of Health and Social Care takes over the responsibilities of NHS England.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Sickle Cell and Thalassaemia Quality Improvement Programme remains committed to improving outcomes and quality of life for people living with sickle cell and thalassaemia. The programme is taking targeted action to align to the commitments within the 10-Year Health Plan to reduce health inequalities nationally, to ensure people in these communities can live longer, healthier lives, spending less time in poor health.
The integration of NHS England into the Department is not due to happen in this financial year, and all programmes of work will be reviewed in alignment with budget setting in future years.
Asked by: Peter Fortune (Conservative - Bromley and Biggin Hill)
Question to the Department for Science, Innovation & Technology:
To ask the Secretary of State for Science, Innovation and Technology, how much Government investment in myelodysplastic syndrome research was in 2023-24; and which public bodies provided that investment.
Answered by Feryal Clark
DSIT funds medical research through UK Research and Innovation (UKRI) and the Department of Health and Social Care funds research through the National Institute for Health and Care Research (NIHR).
UKRI’s Medical Research Council (MRC) supports the best scientific research to improve human health, with work ranging from molecular level science to public health medicine. MRC plays a key role in funding underpinning research which may not be attributable to a specific disease but will benefit medical research more generally.
UKRI delivers a substantial portfolio of researcher-led projects. This includes a wide variety of areas including physiological, biological and mechanistic aspects that are applicable to many diseases, disorders and other conditions.
Details of UKRI and NIHR funding on specific areas is provided in the table below:
| UKRI funding committed in 2023 and 2024 to date | NIHR funding in FY 2023/24 |
Hodgkin Lymphoma | UKRI did not commit any funding for Hodgkin lymphoma research in 2023-24. | NIHR has not allocated funding for research concerning Hodgkin Lymphoma during financial year 2023-24. |
Myelodysplastic Syndrome | UKRI did not commit any new funding for Myelodysplastic Syndrome research in 2023-24. | NIHR has not allocated funding for research concerning Myelodysplastic Syndrome during financial year 2023-24. |
Stem Cell | The total commitment in 2023/24 from UKRI for research concerning Stem Cells was £63,966,085 for 69 awards (14 awards from BBSRC; 4 awards from EPSRC; 6 awards from Innovate UK; 27 awards from MRC with a value of £28,347,161; 3 awards from NC3Rs; 15 awards from centrally managed UKRI schemes). | NIHR has not funded any research concerning Stem Cells during financial year 2023-24. |
Haemophilia | UKRI did not commit any new funding for Haemophilia research in 2023-24. | NIHR allocated £154,000 for high-quality research concerning Haemophilia in 2023-24 |
Sickle Cell | UKRI did not commit any new funding for Sickle Cell research in 2023-24. | NIHR allocated £336,368 for high-quality research concerning Cickle Cell research in the financial year 2023-24 |
Thalassaemia | UKRI did not commit any new funding for Thalassaemia research in 2023-24. | NIHR allocated £158,900 for high-quality research concerning Thalassaemia in the financial year 2023-24 |
Human Immunodeficiency Disease | The total commitment from UKRI in 2023/24 was £13,983,734 for 13 awards (1 award from EPSRC; 8 awards from MRC with a value of £10,800,617 for Human Immunodeficiency Virus (HIV) research; 4 awards from centrally managed UKRI schemes). | NIHR allocated £5,620,876 for high quality research concerning Human Immunodeficiency Disease (HIV and AIDS) in 2023-24 |
Vitamin B12 deficiency | The total commitment across UKRI in 2023-24 for Vitamin B12 deficiency research was £470,348 for 2 awards from Innovate UK. | NIHR has not allocated any funds concerning Vitamin B12 Deficiency during financial year 2023-24. |
Neural Tube Defect Prevention | The total commitment from UKRI in 2023/24 for research concerning Neural Tube Defect Prevention was £4,289,077 for 4 awards (2 awards from MRC with a value of £3,949,400; 1 award from ESRC; 1 award from centrally managed UKRI schemes). | NIHR has not allocated any funds concerning Neural Tube Defect Prevention research during the financial year of 2023-24. |
Malaria vaccination | The total commitment from UKRI in 2023/24 for research concerning Malaria vaccination was £11,697,976 for 7 awards (2 awards from MRC with a value of £3,387,100; 5 awards from centrally managed UKRI schemes). | NIHR has not allocated any funds concerning Malaria Vaccination research during the financial year of 2023-24. The NIHR Oxford Biomedical Research Centre supports the development and testing of malaria vaccines, such as the R21/Matrix-M malaria vaccine. |
Asked by: Peter Fortune (Conservative - Bromley and Biggin Hill)
Question to the Department for Science, Innovation & Technology:
To ask the Secretary of State for Science, Innovation and Technology, how much funding the Government provided for research into Hodgkin lymphoma in the 2023-24 financial year; and through which public bodies that funding was provided.
Answered by Feryal Clark
DSIT funds medical research through UK Research and Innovation (UKRI) and the Department of Health and Social Care funds research through the National Institute for Health and Care Research (NIHR).
UKRI’s Medical Research Council (MRC) supports the best scientific research to improve human health, with work ranging from molecular level science to public health medicine. MRC plays a key role in funding underpinning research which may not be attributable to a specific disease but will benefit medical research more generally.
UKRI delivers a substantial portfolio of researcher-led projects. This includes a wide variety of areas including physiological, biological and mechanistic aspects that are applicable to many diseases, disorders and other conditions.
Details of UKRI and NIHR funding on specific areas is provided in the table below:
| UKRI funding committed in 2023 and 2024 to date | NIHR funding in FY 2023/24 |
Hodgkin Lymphoma | UKRI did not commit any funding for Hodgkin lymphoma research in 2023-24. | NIHR has not allocated funding for research concerning Hodgkin Lymphoma during financial year 2023-24. |
Myelodysplastic Syndrome | UKRI did not commit any new funding for Myelodysplastic Syndrome research in 2023-24. | NIHR has not allocated funding for research concerning Myelodysplastic Syndrome during financial year 2023-24. |
Stem Cell | The total commitment in 2023/24 from UKRI for research concerning Stem Cells was £63,966,085 for 69 awards (14 awards from BBSRC; 4 awards from EPSRC; 6 awards from Innovate UK; 27 awards from MRC with a value of £28,347,161; 3 awards from NC3Rs; 15 awards from centrally managed UKRI schemes). | NIHR has not funded any research concerning Stem Cells during financial year 2023-24. |
Haemophilia | UKRI did not commit any new funding for Haemophilia research in 2023-24. | NIHR allocated £154,000 for high-quality research concerning Haemophilia in 2023-24 |
Sickle Cell | UKRI did not commit any new funding for Sickle Cell research in 2023-24. | NIHR allocated £336,368 for high-quality research concerning Cickle Cell research in the financial year 2023-24 |
Thalassaemia | UKRI did not commit any new funding for Thalassaemia research in 2023-24. | NIHR allocated £158,900 for high-quality research concerning Thalassaemia in the financial year 2023-24 |
Human Immunodeficiency Disease | The total commitment from UKRI in 2023/24 was £13,983,734 for 13 awards (1 award from EPSRC; 8 awards from MRC with a value of £10,800,617 for Human Immunodeficiency Virus (HIV) research; 4 awards from centrally managed UKRI schemes). | NIHR allocated £5,620,876 for high quality research concerning Human Immunodeficiency Disease (HIV and AIDS) in 2023-24 |
Vitamin B12 deficiency | The total commitment across UKRI in 2023-24 for Vitamin B12 deficiency research was £470,348 for 2 awards from Innovate UK. | NIHR has not allocated any funds concerning Vitamin B12 Deficiency during financial year 2023-24. |
Neural Tube Defect Prevention | The total commitment from UKRI in 2023/24 for research concerning Neural Tube Defect Prevention was £4,289,077 for 4 awards (2 awards from MRC with a value of £3,949,400; 1 award from ESRC; 1 award from centrally managed UKRI schemes). | NIHR has not allocated any funds concerning Neural Tube Defect Prevention research during the financial year of 2023-24. |
Malaria vaccination | The total commitment from UKRI in 2023/24 for research concerning Malaria vaccination was £11,697,976 for 7 awards (2 awards from MRC with a value of £3,387,100; 5 awards from centrally managed UKRI schemes). | NIHR has not allocated any funds concerning Malaria Vaccination research during the financial year of 2023-24. The NIHR Oxford Biomedical Research Centre supports the development and testing of malaria vaccines, such as the R21/Matrix-M malaria vaccine. |
Asked by: Peter Fortune (Conservative - Bromley and Biggin Hill)
Question to the Department for Science, Innovation & Technology:
To ask the Secretary of State for Science, Innovation and Technology, how much Government funding there was into stem cell research in 2023-24; and which public bodies provided that funding.
Answered by Feryal Clark
DSIT funds medical research through UK Research and Innovation (UKRI) and the Department of Health and Social Care funds research through the National Institute for Health and Care Research (NIHR).
UKRI’s Medical Research Council (MRC) supports the best scientific research to improve human health, with work ranging from molecular level science to public health medicine. MRC plays a key role in funding underpinning research which may not be attributable to a specific disease but will benefit medical research more generally.
UKRI delivers a substantial portfolio of researcher-led projects. This includes a wide variety of areas including physiological, biological and mechanistic aspects that are applicable to many diseases, disorders and other conditions.
Details of UKRI and NIHR funding on specific areas is provided in the table below:
| UKRI funding committed in 2023 and 2024 to date | NIHR funding in FY 2023/24 |
Hodgkin Lymphoma | UKRI did not commit any funding for Hodgkin lymphoma research in 2023-24. | NIHR has not allocated funding for research concerning Hodgkin Lymphoma during financial year 2023-24. |
Myelodysplastic Syndrome | UKRI did not commit any new funding for Myelodysplastic Syndrome research in 2023-24. | NIHR has not allocated funding for research concerning Myelodysplastic Syndrome during financial year 2023-24. |
Stem Cell | The total commitment in 2023/24 from UKRI for research concerning Stem Cells was £63,966,085 for 69 awards (14 awards from BBSRC; 4 awards from EPSRC; 6 awards from Innovate UK; 27 awards from MRC with a value of £28,347,161; 3 awards from NC3Rs; 15 awards from centrally managed UKRI schemes). | NIHR has not funded any research concerning Stem Cells during financial year 2023-24. |
Haemophilia | UKRI did not commit any new funding for Haemophilia research in 2023-24. | NIHR allocated £154,000 for high-quality research concerning Haemophilia in 2023-24 |
Sickle Cell | UKRI did not commit any new funding for Sickle Cell research in 2023-24. | NIHR allocated £336,368 for high-quality research concerning Cickle Cell research in the financial year 2023-24 |
Thalassaemia | UKRI did not commit any new funding for Thalassaemia research in 2023-24. | NIHR allocated £158,900 for high-quality research concerning Thalassaemia in the financial year 2023-24 |
Human Immunodeficiency Disease | The total commitment from UKRI in 2023/24 was £13,983,734 for 13 awards (1 award from EPSRC; 8 awards from MRC with a value of £10,800,617 for Human Immunodeficiency Virus (HIV) research; 4 awards from centrally managed UKRI schemes). | NIHR allocated £5,620,876 for high quality research concerning Human Immunodeficiency Disease (HIV and AIDS) in 2023-24 |
Vitamin B12 deficiency | The total commitment across UKRI in 2023-24 for Vitamin B12 deficiency research was £470,348 for 2 awards from Innovate UK. | NIHR has not allocated any funds concerning Vitamin B12 Deficiency during financial year 2023-24. |
Neural Tube Defect Prevention | The total commitment from UKRI in 2023/24 for research concerning Neural Tube Defect Prevention was £4,289,077 for 4 awards (2 awards from MRC with a value of £3,949,400; 1 award from ESRC; 1 award from centrally managed UKRI schemes). | NIHR has not allocated any funds concerning Neural Tube Defect Prevention research during the financial year of 2023-24. |
Malaria vaccination | The total commitment from UKRI in 2023/24 for research concerning Malaria vaccination was £11,697,976 for 7 awards (2 awards from MRC with a value of £3,387,100; 5 awards from centrally managed UKRI schemes). | NIHR has not allocated any funds concerning Malaria Vaccination research during the financial year of 2023-24. The NIHR Oxford Biomedical Research Centre supports the development and testing of malaria vaccines, such as the R21/Matrix-M malaria vaccine. |
Asked by: Peter Fortune (Conservative - Bromley and Biggin Hill)
Question to the Department for Science, Innovation & Technology:
To ask the Secretary of State for Science, Innovation and Technology, how much Government funding there was into haemophilia research in 2023-24; and which public bodies provided that funding.
Answered by Feryal Clark
DSIT funds medical research through UK Research and Innovation (UKRI) and the Department of Health and Social Care funds research through the National Institute for Health and Care Research (NIHR).
UKRI’s Medical Research Council (MRC) supports the best scientific research to improve human health, with work ranging from molecular level science to public health medicine. MRC plays a key role in funding underpinning research which may not be attributable to a specific disease but will benefit medical research more generally.
UKRI delivers a substantial portfolio of researcher-led projects. This includes a wide variety of areas including physiological, biological and mechanistic aspects that are applicable to many diseases, disorders and other conditions.
Details of UKRI and NIHR funding on specific areas is provided in the table below:
| UKRI funding committed in 2023 and 2024 to date | NIHR funding in FY 2023/24 |
Hodgkin Lymphoma | UKRI did not commit any funding for Hodgkin lymphoma research in 2023-24. | NIHR has not allocated funding for research concerning Hodgkin Lymphoma during financial year 2023-24. |
Myelodysplastic Syndrome | UKRI did not commit any new funding for Myelodysplastic Syndrome research in 2023-24. | NIHR has not allocated funding for research concerning Myelodysplastic Syndrome during financial year 2023-24. |
Stem Cell | The total commitment in 2023/24 from UKRI for research concerning Stem Cells was £63,966,085 for 69 awards (14 awards from BBSRC; 4 awards from EPSRC; 6 awards from Innovate UK; 27 awards from MRC with a value of £28,347,161; 3 awards from NC3Rs; 15 awards from centrally managed UKRI schemes). | NIHR has not funded any research concerning Stem Cells during financial year 2023-24. |
Haemophilia | UKRI did not commit any new funding for Haemophilia research in 2023-24. | NIHR allocated £154,000 for high-quality research concerning Haemophilia in 2023-24 |
Sickle Cell | UKRI did not commit any new funding for Sickle Cell research in 2023-24. | NIHR allocated £336,368 for high-quality research concerning Cickle Cell research in the financial year 2023-24 |
Thalassaemia | UKRI did not commit any new funding for Thalassaemia research in 2023-24. | NIHR allocated £158,900 for high-quality research concerning Thalassaemia in the financial year 2023-24 |
Human Immunodeficiency Disease | The total commitment from UKRI in 2023/24 was £13,983,734 for 13 awards (1 award from EPSRC; 8 awards from MRC with a value of £10,800,617 for Human Immunodeficiency Virus (HIV) research; 4 awards from centrally managed UKRI schemes). | NIHR allocated £5,620,876 for high quality research concerning Human Immunodeficiency Disease (HIV and AIDS) in 2023-24 |
Vitamin B12 deficiency | The total commitment across UKRI in 2023-24 for Vitamin B12 deficiency research was £470,348 for 2 awards from Innovate UK. | NIHR has not allocated any funds concerning Vitamin B12 Deficiency during financial year 2023-24. |
Neural Tube Defect Prevention | The total commitment from UKRI in 2023/24 for research concerning Neural Tube Defect Prevention was £4,289,077 for 4 awards (2 awards from MRC with a value of £3,949,400; 1 award from ESRC; 1 award from centrally managed UKRI schemes). | NIHR has not allocated any funds concerning Neural Tube Defect Prevention research during the financial year of 2023-24. |
Malaria vaccination | The total commitment from UKRI in 2023/24 for research concerning Malaria vaccination was £11,697,976 for 7 awards (2 awards from MRC with a value of £3,387,100; 5 awards from centrally managed UKRI schemes). | NIHR has not allocated any funds concerning Malaria Vaccination research during the financial year of 2023-24. The NIHR Oxford Biomedical Research Centre supports the development and testing of malaria vaccines, such as the R21/Matrix-M malaria vaccine. |
Asked by: Peter Fortune (Conservative - Bromley and Biggin Hill)
Question to the Department for Science, Innovation & Technology:
To ask the Secretary of State for Science, Innovation and Technology, how much Government funding there was into human immunodeficiency disease research in 2023-24; and which public bodies provided that funding.
Answered by Feryal Clark
DSIT funds medical research through UK Research and Innovation (UKRI) and the Department of Health and Social Care funds research through the National Institute for Health and Care Research (NIHR).
UKRI’s Medical Research Council (MRC) supports the best scientific research to improve human health, with work ranging from molecular level science to public health medicine. MRC plays a key role in funding underpinning research which may not be attributable to a specific disease but will benefit medical research more generally.
UKRI delivers a substantial portfolio of researcher-led projects. This includes a wide variety of areas including physiological, biological and mechanistic aspects that are applicable to many diseases, disorders and other conditions.
Details of UKRI and NIHR funding on specific areas is provided in the table below:
| UKRI funding committed in 2023 and 2024 to date | NIHR funding in FY 2023/24 |
Hodgkin Lymphoma | UKRI did not commit any funding for Hodgkin lymphoma research in 2023-24. | NIHR has not allocated funding for research concerning Hodgkin Lymphoma during financial year 2023-24. |
Myelodysplastic Syndrome | UKRI did not commit any new funding for Myelodysplastic Syndrome research in 2023-24. | NIHR has not allocated funding for research concerning Myelodysplastic Syndrome during financial year 2023-24. |
Stem Cell | The total commitment in 2023/24 from UKRI for research concerning Stem Cells was £63,966,085 for 69 awards (14 awards from BBSRC; 4 awards from EPSRC; 6 awards from Innovate UK; 27 awards from MRC with a value of £28,347,161; 3 awards from NC3Rs; 15 awards from centrally managed UKRI schemes). | NIHR has not funded any research concerning Stem Cells during financial year 2023-24. |
Haemophilia | UKRI did not commit any new funding for Haemophilia research in 2023-24. | NIHR allocated £154,000 for high-quality research concerning Haemophilia in 2023-24 |
Sickle Cell | UKRI did not commit any new funding for Sickle Cell research in 2023-24. | NIHR allocated £336,368 for high-quality research concerning Cickle Cell research in the financial year 2023-24 |
Thalassaemia | UKRI did not commit any new funding for Thalassaemia research in 2023-24. | NIHR allocated £158,900 for high-quality research concerning Thalassaemia in the financial year 2023-24 |
Human Immunodeficiency Disease | The total commitment from UKRI in 2023/24 was £13,983,734 for 13 awards (1 award from EPSRC; 8 awards from MRC with a value of £10,800,617 for Human Immunodeficiency Virus (HIV) research; 4 awards from centrally managed UKRI schemes). | NIHR allocated £5,620,876 for high quality research concerning Human Immunodeficiency Disease (HIV and AIDS) in 2023-24 |
Vitamin B12 deficiency | The total commitment across UKRI in 2023-24 for Vitamin B12 deficiency research was £470,348 for 2 awards from Innovate UK. | NIHR has not allocated any funds concerning Vitamin B12 Deficiency during financial year 2023-24. |
Neural Tube Defect Prevention | The total commitment from UKRI in 2023/24 for research concerning Neural Tube Defect Prevention was £4,289,077 for 4 awards (2 awards from MRC with a value of £3,949,400; 1 award from ESRC; 1 award from centrally managed UKRI schemes). | NIHR has not allocated any funds concerning Neural Tube Defect Prevention research during the financial year of 2023-24. |
Malaria vaccination | The total commitment from UKRI in 2023/24 for research concerning Malaria vaccination was £11,697,976 for 7 awards (2 awards from MRC with a value of £3,387,100; 5 awards from centrally managed UKRI schemes). | NIHR has not allocated any funds concerning Malaria Vaccination research during the financial year of 2023-24. The NIHR Oxford Biomedical Research Centre supports the development and testing of malaria vaccines, such as the R21/Matrix-M malaria vaccine. |
Asked by: Peter Fortune (Conservative - Bromley and Biggin Hill)
Question to the Department for Science, Innovation & Technology:
To ask the Secretary of State for Science, Innovation and Technology, how much Government funding there was into vitamin B12 deficiency research in 2023-24; and which public bodies provided that funding.
Answered by Feryal Clark
DSIT funds medical research through UK Research and Innovation (UKRI) and the Department of Health and Social Care funds research through the National Institute for Health and Care Research (NIHR).
UKRI’s Medical Research Council (MRC) supports the best scientific research to improve human health, with work ranging from molecular level science to public health medicine. MRC plays a key role in funding underpinning research which may not be attributable to a specific disease but will benefit medical research more generally.
UKRI delivers a substantial portfolio of researcher-led projects. This includes a wide variety of areas including physiological, biological and mechanistic aspects that are applicable to many diseases, disorders and other conditions.
Details of UKRI and NIHR funding on specific areas is provided in the table below:
| UKRI funding committed in 2023 and 2024 to date | NIHR funding in FY 2023/24 |
Hodgkin Lymphoma | UKRI did not commit any funding for Hodgkin lymphoma research in 2023-24. | NIHR has not allocated funding for research concerning Hodgkin Lymphoma during financial year 2023-24. |
Myelodysplastic Syndrome | UKRI did not commit any new funding for Myelodysplastic Syndrome research in 2023-24. | NIHR has not allocated funding for research concerning Myelodysplastic Syndrome during financial year 2023-24. |
Stem Cell | The total commitment in 2023/24 from UKRI for research concerning Stem Cells was £63,966,085 for 69 awards (14 awards from BBSRC; 4 awards from EPSRC; 6 awards from Innovate UK; 27 awards from MRC with a value of £28,347,161; 3 awards from NC3Rs; 15 awards from centrally managed UKRI schemes). | NIHR has not funded any research concerning Stem Cells during financial year 2023-24. |
Haemophilia | UKRI did not commit any new funding for Haemophilia research in 2023-24. | NIHR allocated £154,000 for high-quality research concerning Haemophilia in 2023-24 |
Sickle Cell | UKRI did not commit any new funding for Sickle Cell research in 2023-24. | NIHR allocated £336,368 for high-quality research concerning Cickle Cell research in the financial year 2023-24 |
Thalassaemia | UKRI did not commit any new funding for Thalassaemia research in 2023-24. | NIHR allocated £158,900 for high-quality research concerning Thalassaemia in the financial year 2023-24 |
Human Immunodeficiency Disease | The total commitment from UKRI in 2023/24 was £13,983,734 for 13 awards (1 award from EPSRC; 8 awards from MRC with a value of £10,800,617 for Human Immunodeficiency Virus (HIV) research; 4 awards from centrally managed UKRI schemes). | NIHR allocated £5,620,876 for high quality research concerning Human Immunodeficiency Disease (HIV and AIDS) in 2023-24 |
Vitamin B12 deficiency | The total commitment across UKRI in 2023-24 for Vitamin B12 deficiency research was £470,348 for 2 awards from Innovate UK. | NIHR has not allocated any funds concerning Vitamin B12 Deficiency during financial year 2023-24. |
Neural Tube Defect Prevention | The total commitment from UKRI in 2023/24 for research concerning Neural Tube Defect Prevention was £4,289,077 for 4 awards (2 awards from MRC with a value of £3,949,400; 1 award from ESRC; 1 award from centrally managed UKRI schemes). | NIHR has not allocated any funds concerning Neural Tube Defect Prevention research during the financial year of 2023-24. |
Malaria vaccination | The total commitment from UKRI in 2023/24 for research concerning Malaria vaccination was £11,697,976 for 7 awards (2 awards from MRC with a value of £3,387,100; 5 awards from centrally managed UKRI schemes). | NIHR has not allocated any funds concerning Malaria Vaccination research during the financial year of 2023-24. The NIHR Oxford Biomedical Research Centre supports the development and testing of malaria vaccines, such as the R21/Matrix-M malaria vaccine. |
Asked by: Peter Fortune (Conservative - Bromley and Biggin Hill)
Question to the Department for Science, Innovation & Technology:
To ask the Secretary of State for Science, Innovation and Technology, how much Government funding there was into thalassaemia research in 2023-24; and which public bodies provided that funding.
Answered by Feryal Clark
DSIT funds medical research through UK Research and Innovation (UKRI) and the Department of Health and Social Care funds research through the National Institute for Health and Care Research (NIHR).
UKRI’s Medical Research Council (MRC) supports the best scientific research to improve human health, with work ranging from molecular level science to public health medicine. MRC plays a key role in funding underpinning research which may not be attributable to a specific disease but will benefit medical research more generally.
UKRI delivers a substantial portfolio of researcher-led projects. This includes a wide variety of areas including physiological, biological and mechanistic aspects that are applicable to many diseases, disorders and other conditions.
Details of UKRI and NIHR funding on specific areas is provided in the table below:
| UKRI funding committed in 2023 and 2024 to date | NIHR funding in FY 2023/24 |
Hodgkin Lymphoma | UKRI did not commit any funding for Hodgkin lymphoma research in 2023-24. | NIHR has not allocated funding for research concerning Hodgkin Lymphoma during financial year 2023-24. |
Myelodysplastic Syndrome | UKRI did not commit any new funding for Myelodysplastic Syndrome research in 2023-24. | NIHR has not allocated funding for research concerning Myelodysplastic Syndrome during financial year 2023-24. |
Stem Cell | The total commitment in 2023/24 from UKRI for research concerning Stem Cells was £63,966,085 for 69 awards (14 awards from BBSRC; 4 awards from EPSRC; 6 awards from Innovate UK; 27 awards from MRC with a value of £28,347,161; 3 awards from NC3Rs; 15 awards from centrally managed UKRI schemes). | NIHR has not funded any research concerning Stem Cells during financial year 2023-24. |
Haemophilia | UKRI did not commit any new funding for Haemophilia research in 2023-24. | NIHR allocated £154,000 for high-quality research concerning Haemophilia in 2023-24 |
Sickle Cell | UKRI did not commit any new funding for Sickle Cell research in 2023-24. | NIHR allocated £336,368 for high-quality research concerning Cickle Cell research in the financial year 2023-24 |
Thalassaemia | UKRI did not commit any new funding for Thalassaemia research in 2023-24. | NIHR allocated £158,900 for high-quality research concerning Thalassaemia in the financial year 2023-24 |
Human Immunodeficiency Disease | The total commitment from UKRI in 2023/24 was £13,983,734 for 13 awards (1 award from EPSRC; 8 awards from MRC with a value of £10,800,617 for Human Immunodeficiency Virus (HIV) research; 4 awards from centrally managed UKRI schemes). | NIHR allocated £5,620,876 for high quality research concerning Human Immunodeficiency Disease (HIV and AIDS) in 2023-24 |
Vitamin B12 deficiency | The total commitment across UKRI in 2023-24 for Vitamin B12 deficiency research was £470,348 for 2 awards from Innovate UK. | NIHR has not allocated any funds concerning Vitamin B12 Deficiency during financial year 2023-24. |
Neural Tube Defect Prevention | The total commitment from UKRI in 2023/24 for research concerning Neural Tube Defect Prevention was £4,289,077 for 4 awards (2 awards from MRC with a value of £3,949,400; 1 award from ESRC; 1 award from centrally managed UKRI schemes). | NIHR has not allocated any funds concerning Neural Tube Defect Prevention research during the financial year of 2023-24. |
Malaria vaccination | The total commitment from UKRI in 2023/24 for research concerning Malaria vaccination was £11,697,976 for 7 awards (2 awards from MRC with a value of £3,387,100; 5 awards from centrally managed UKRI schemes). | NIHR has not allocated any funds concerning Malaria Vaccination research during the financial year of 2023-24. The NIHR Oxford Biomedical Research Centre supports the development and testing of malaria vaccines, such as the R21/Matrix-M malaria vaccine. |